Protective immunity against lethal F. tularensis holarctica LVS provided by vaccination with selected novel CD8+ T cell epitopes

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Rotem, Shahar ^a   Cohen, Ofer ^a   Bar Haim, Erez ^a   Bar On, Liat ^a   Ehrlich, Sharon ^a   Shafferman, Avigdor ^a  

^a ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL VACCINE; CD8 ANTIGEN; DNA VACCINE; EPITOPE; FRANCISELLA TULARENSIS HOLARCTICA VACCINE; LIVE VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL STRAIN; CD8+ T LYMPHOCYTE; CELL SPECIFICITY; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DNA FRAGMENTATION; DNA VECTOR; FEMALE; FRANCISELLA TULARENSIS HOLARCTICA; FRANCISELLA TULARENSIS HOLARCTICA INFECTION; GENE EXPRESSION; IMMUNIZATION; LD 50; LETHALITY; MOUSE; NONHUMAN; PROTEIN DEPLETION; SINGLE DRUG DOSE; TULAREMIA; VACCINATION;

ANIMALS; BACTERIAL VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; EPITOPES, T-LYMPHOCYTE; FEMALE; FRANCISELLA TULARENSIS; IMMUNOLOGIC MEMORY; LYMPHOCYTE ACTIVATION; MICE; MICE, KNOCKOUT; TULAREMIA; VACCINES, ATTENUATED;

EID: 84896446035     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0085215     Document Type: Article

References (43)

1. Titball RW (2008) Vaccines against intracellular bacterial pathogens. Drug Discovery Today 13: 596-600.
2. McLendon MK, Apicella MA, Allen LA (2006) Francisella tularensis: taxonomy, genetics, and Immunopathogenesis of a potential agent of biowarfare. Annu Rev Microbiol 60: 167-185. (Pubitemid 44627945)
3. Dennis DT, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, et al. (2001) Tularemia as a biological weapon: medical and public health management. Jama 285: 2763-2773. (Pubitemid 32525374)
4. Oyston PC, Sjostedt A, Titball RW (2004) Tularaemia: bioterrorism defence renews interest in Francisella tularensis. Nat Rev Microbiol 2: 967-978. (Pubitemid 39562535)
5. Fortier AH, Leiby DA, Narayanan RB, Asafoadjei E, Crawford RM, et al. (1995) Growth of Francisella tularensis LVS in macrophages: the acidic intracellular compartment provides essential iron required for growth. Infect Immun 63: 1478-1483.
6. Bolger CE, Forestal CA, Italo JK, Benach JL, Furie MB (2005) The live vaccine strain of Francisella tularensis replicates in human and murine macrophages but induces only the human cells to secrete proinflammatory cytokines. J Leukoc Biol 77: 893-897. (Pubitemid 40770840)
7. Anthony LD, Burke RD, Nano FE (1991) Growth of Francisella spp. in rodent macrophages. Infect Immun 59: 3291-3296.
8. Conlan JW, Sjostedt A, North RJ (1994) CD4+ and CD8+ T-cell-dependent and -independent host defense mechanisms can operate to control and resolve primary and secondary Francisella tularensis LVS infection in mice. Infect Immun 62: 5603-5607. (Pubitemid 24365007)
9. Yee D, Rhinehart-Jones TR, Elkins KL (1996) Loss of either CD4+ or CD8+ T cells does not affect the magnitude of protective immunity to an intracellular pathogen, Francisella tularensis strain LVS. J Immunol 157: 5042-5048. (Pubitemid 126449585)
10. Elkins KL, Rhinehart-Jones TR, Culkin SJ, Yee D, Winegar RK (1996) Minimal requirements for murine resistance to infection with Francisella tularensis LVS. Infect Immun 64: 3288-3293. (Pubitemid 26256178)
11. Wayne Conlan J, Shen H, Kuolee R, Zhao X, Chen W (2005) Aerosol-, but not intradermal-immunization with the live vaccine strain of Francisella tularensis protects mice against subsequent aerosol challenge with a highly virulent type A strain of the pathogen by an alphabeta T cell- and interferon gamma- dependent mechanism. Vaccine 23: 2477-2485.
12. Wu TH, Hutt JA, Garrison KA, Berliba LS, Zhou Y, et al. (2005) Intranasal vaccination induces protective immunity against intranasal infection with virulent Francisella tularensis biovar A. Infect Immun 73: 2644-2654. (Pubitemid 40570329)
13. Bakshi CS, Malik M, Mahawar M, Kirimanjeswara GS, Hazlett KR, et al. (2008) An improved vaccine for prevention of respiratory tularemia caused by Francisella tularensis SchuS4 strain. Vaccine 26: 5276-5288.
14. Tigertt WD (1962) Soviet viable Pasteurella tularensis vaccines. A review of selected articles. Bacteriol Rev 26: 354-373.
15. Eigelsbach HT, Downs CM (1961) Prophylactic effectiveness of live and killed tularemia vaccines. I. Production of vaccine and evaluation in the white mouse and guinea pig. J Immunol 87: 415-425.
16. Fortier AH, Slayter MV, Ziemba R, Meltzer MS, Nacy CA (1991) Live vaccine strain of Francisella tularensis: infection and immunity in mice. Infect Immun 59: 2922-2928.
17. Ellis J, Oyston PC, Green M, Titball RW (2002) Tularemia. Clin Microbiol Rev 15: 631-646. (Pubitemid 41184082)
18. Conlan JW (2011) Tularemia vaccines: recent developments and remaining hurdles. Future Microbiol 6: 391-405.
19. Conlan W, Sjostedt A (2010) Novel live vaccine candidates against airborne Francisella tularensis. In: Shafferman A OA, Velan B, editor. The Challenge of Highly Pathogenic Microorganisms-Mechanisms of Virulence and Novel Medical Countermeasures. London-New York: Springer. 213-218.
20. Oyston PC (2009) Francisella tularensis vaccines. Vaccine 27 Suppl 4: D48-51.
21. Barry EM, Cole LE, Santiago AE (2009) Vaccines against tularemia. Hum Vaccin 5: 832-838.
22. Griffin KF, Oyston PC, Titball RW (2007) Francisella tularensis vaccines. FEMS Immunol Med Microbiol 49: 315-323. (Pubitemid 46435019)
23. Mann BJ, Ark NM (2009) Rationally designed tularemia vaccines. Expert Rev Vaccines 8: 877-885.
24. McMurry JA, Moise L, Gregory SH, De Groot AS (2007) Tularemia vaccines - an overview. Med Health R I 90: 311-314.
25. Gregory SH, Mott S, Phung J, Lee J, Moise L, et al. (2009) Epitope-based vaccination against pneumonic tularemia. Vaccine 27: 5299-5306.
26. Zvi A, Rotem S, Bar-Haim E, Cohen O, Shafferman A (2011) Whole-genome immunoinformatic analysis of F. tularensis: predicted CTL epitopes clustered in hotspots are prone to elicit a T-cell response. PLoS One 6: e20050.
27. Zvi A, Rotem S, Cohen O, Shafferman A (2012) Clusters versus Affinity-Based Approaches in F. tularensis Whole Genome Search of CTL Epitopes. PLoS One 7: e36440.
28. Bar-Haim E, Gat O, Markel G, Cohen H, Shafferman A, et al. (2008) Interrelationship between dendritic cell trafficking and Francisella tularensis dissemination following airway infection. PLoS Pathog 4: e1000211.
29. Rotem S, Bar-Haim E, Cohen H, Elia U, Ber R, et al. (2012) Consequences of delayed ciprofloxacin and doxycycline treatment regimens against Francisella tularensis airway infection. Antimicrob Agents Chemother 56: 5406-5408.
30. Teixeira FM, Teixeira HC, Ferreira AP, Rodrigues MF, Azevedo V, et al. (2006) DNA vaccine using Mycobacterium bovis Ag85B antigen induces partial protection against experimental infection in BALB/c mice. Clin Vaccine Immunol 13: 930-935. (Pubitemid 44409633)
31. Grosfeld H, Cohen S, Bino T, Flashner Y, Ber R, et al. (2003) Effective protective immunity to Yersinia pestis infection conferred by DNA vaccine coding for derivatives of the F1 capsular antigen. Infect Immun 71: 374-383. (Pubitemid 36026041)
32. Versage JL, Severin DD, Chu MC, Petersen JM (2003) Development of a multitarget real-time TaqMan PCR assay for enhanced detection of Francisella tularensis in complex specimens. J Clin Microbiol 41: 5492-5499. (Pubitemid 37543235)
33. Chen W, Shen H, Webb A, KuoLee R, Conlan JW (2003) Tularemia in BALB/c and C57BL/6 mice vaccinated with Francisella tularensis LVS and challenged intradermally, or by aerosol with virulent isolates of the pathogen: protection varies depending on pathogen virulence, route of exposure, and host genetic background. Vaccine 21: 3690-3700. (Pubitemid 37345131)
34. Conlan WJ, Shen H, Kuolee R, Zhao X, Chen W (2005) Aerosol-, but not intradermal-immunization with the live vaccine strain of Francisella tularensis protects mice against subsequent aerosol challenge with a highly virulent type A strain of the pathogen by an alphabeta T cell- and interferon gamma- dependent mechanism. Vaccine 23: 2477-2485.
35. Harty JT, Bevan MJ (1992) CD8+ T cells specific for a single nonamer epitope of Listeria monocytogenes are protective in vivo. J Exp Med 175: 1531-1538.
36. Pamer EG, Harty JT, Bevan MJ (1991) Precise prediction of a dominant class I MHC-restricted epitope of Listeria monocytogenes. Nature 353: 852-855. (Pubitemid 21912640)
37. 3- by gene gun DNA vaccination with a minigene encoding a CTL epitope of Listeria monocytogenes. Vaccine 19: 4297-4306.
38. Lipford GB, Lehn N, Bauer S, Heeg K, Wagner H (1994) The immunodominant peptide from listeriolysin in Quil A liposomes vaccinates CD8+ cytolytic T cells and confers protection to infection. Immunol Lett 40: 101-104. (Pubitemid 24175035)
39. Ozawa Y, Suda T, Nagata T, Hashimoto D, Nakamura Y, et al. (2009) Mucosal vaccine using CTL epitope-pulsed dendritic cell confers protection for intracellular pathogen. Am J Respir Cell Mol Biol 41: 440-448.
40. Zhang Y, Mena P, Romanov G, Lin JS, Smiley ST, et al. (2012) A protective epitope in type III effector YopE is a major CD8 T cell antigen during primary infection with Yersinia pseudotuberculosis. Infect Immun 80: 206-214.
41. Lin JS, Szaba FM, Kummer LW, Chromy BA, Smiley ST (2011) Yersinia pestis YopE contains a dominant CD8 T cell epitope that confers protection in a mouse model of pneumonic plague. J Immunol 187: 897-904.
42. Wizel B, Starcher BC, Samten B, Chroneos Z, Barnes PF, et al. (2002) Multiple Chlamydia pneumoniae antigens prime CD8+ Tc1 responses that inhibit intracellular growth of this vacuolar pathogen. J Immunol 169: 2524-2535. (Pubitemid 34920997)
43. Pinchuk I, Starcher BC, Livingston B, Tvninnereim A, Wu S, et al. (2005) A CD8+ T cell heptaepitope minigene vaccine induces protective immunity against Chlamydia pneumoniae. J Immunol 174: 5729-5739. (Pubitemid 40593216)